Aptiv Solutions, Inc. has acquired SRA International’s contract research organization, SRA Global Clinical Development (GCD). The transaction is effective immediately. Financial terms were not disclosed.

“We believe the GCD business, as a part of Aptiv Solutions, has greater opportunity to pursue a wider range of initiatives that align with its mission,” said SRA president and chief executive officer Bill Ballhaus. In March 2011, SRA Int’l. announced its decision to divest the CRO and its wholly owned subsidiaries.

As part of its initiative, Aptiv Solutions has integrated the resources of: Averion International, Trio Clinical Resourcing, Fulcrum Pharma, ClinResearch, Niphix and ADDPLAN.